Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 06/25/17
End: 06/30/21
Due: 06/30/22
Phase: N/A
Priority: Normal
Start: 06/21/19
End: 12/15/24
Due: 12/15/25
Phase: N/A
Priority: Normal
Start: 03/12/20
End: 10/24/21
Due: 10/24/22
Phase: N/A
Priority: Normal
Start: 11/29/21
End: 08/31/25
Due: 08/31/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma | NCT03088176 | West Cancer Center | user2@example.com | None | 2017-06-25 | 2021-06-30 | 2022-06-30 | - | - | 2025-07-14 |
| Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast | NCT03812393 | West Cancer Center | user2@example.com | None | 2019-06-21 | 2024-12-15 | 2025-12-15 | - | - | 2025-07-14 |
| Evaluation of a Mobile App to Promote Social Support for Oncology Patients | NCT04331678 | West Cancer Center | user2@example.com | None | 2020-03-12 | 2021-10-24 | 2022-10-24 | - | - | 2025-07-14 |
| Niraparib and Dostarlimab in HRD Solid Tumors | NCT04983745 | West Cancer Center | user2@example.com | None | 2021-11-29 | 2025-08-31 | 2026-08-31 | - | - | 2025-07-14 |